Theravance Biopharma Inc. priced an upsized $94.1 million public offering on Friday, saying it would sell about 4.77 million shares at $21 each as it moves to build a strong balance sheet capable of supporting two key development programs alongside further commercial efforts on Vibativ (telavancin) and advancement of the rest of its pipeline.